scholarly journals Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)

2018 ◽  
Vol 07 (02) ◽  
pp. 151-155
Author(s):  
M. Singhal ◽  
T. P. Sahoo ◽  
S. Aggarwal ◽  
A. Singhvi ◽  
V. Kaushal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Early Breast Cancer ◽  
Early Stage ◽  
Practical Experience ◽  
Expert Group ◽  
Ovarian Suppression ◽  
Consensus Recommendations ◽  
New Treatment ◽  
Single Modality

AbstractSubstantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefits exist with ovarian suppression plus multiple adjuvant therapy which provides a new treatment option that reduces the risk of recurrence in early breast cancer. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

scholarly journals Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling

2018 ◽  
Vol 07 (02) ◽  
pp. 096-101 ◽  
Author(s):  
A. Aggarwal ◽  
A. Vaid ◽  
A. Ramesh ◽  
Purvish M. Parikh ◽  
S. Purohit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Early Breast Cancer ◽  
Early Stage ◽  
Practical Experience ◽  
Specific Reference ◽  
Chemotherapy Response ◽  
Breast Cancers ◽  
Early Stage Disease ◽  
Consensus Recommendations

AbstractBreast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. The use of gene expression assays for early stage disease is already common practice. These tests have found a place in risk stratifying the heterogeneous group of stage I–II breast cancers for recurrence, for predicting chemotherapy response, and for predicting breast cancer-related mortality. Most guidelines for hormone receptor (HR)–positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost. Expert oncologist discussed about strategies of gene expression assays and aid in chemotherapy recommendations for treatment of HR + ve EBC and the expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

scholarly journals Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer

2018 ◽  
Vol 07 (02) ◽  
pp. 102-105
Author(s):  
A. Bahl ◽  
R. Singh ◽  
J. Wadhwa ◽  
S. Gupta ◽  
M. Ahmed ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Practical Experience ◽  
Expert Group ◽  
Over Expression ◽  
Large Group ◽  
Consensus Recommendations ◽  
Prognostic Feature

AbstractOver-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations with regards to the use of these agents and the management of HER2 neu early breast cancer for the benefit of community oncologists.

scholarly journals Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women

2018 ◽  
Vol 07 (02) ◽  
pp. 123-126
Author(s):  
Govind Babu ◽  
A. Goel ◽  
S. Agarwal ◽  
S. Gupta ◽  
P. Kumar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cause Of Death ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Older Patients ◽  
Elderly Women ◽  
Practical Experience ◽  
Expert Group ◽  
Consensus Recommendations ◽  
Hormone Receptor Positive

AbstractBreast cancer is a leading cause of death among women, and its incidence increases with age. Currently the treatment of breast cancer in older patients is almost identical to their younger counterparts. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations for the benefit of community oncologists regarding the management of early breast cancer specifically in elderly women.

scholarly journals Practical consensus recommendations regarding role of mastectomy in metastatic breast cancer

2018 ◽  
Vol 07 (02) ◽  
pp. 079-082 ◽  
Author(s):  
S. P. Somsekhar ◽  
K. Geeta ◽  
R. Jain ◽  
R. Nayyer ◽  
S. Halder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Advanced Breast Cancer ◽  
Metastatic Breast ◽  
Local Therapy ◽  
Practical Experience ◽  
Main Question ◽  
Expert Group ◽  
Consensus Recommendations

AbstractWhether to recommend mastectomy in metastatic disease or not has been a matter of debate. Is local therapy, such as mastectomy, of any benefit in advanced breast cancer is the main question. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations for the benefit of community oncologists.

scholarly journals The role of aromatase inhibitors as adjuvant therapy in early breast cancer

2004 ◽  
Vol 7 (10) ◽  
Author(s):  
A. U. Buzdar
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Early Stage ◽  
Clinical Status ◽  
Hormone Receptor Positive ◽  
Breast Cancer Study ◽  
Adjuvant Breast Cancer

Endocrine therapy is now established as the treatment option of choice for postmenopausal women with hormone receptor-positive advanced breast cancer. The benefit of the third-generation aromatase inhibitors (AIs) in this setting has prompted their evaluation in the treatment of early breast cancer. This article reviews the current clinical status of AIs as adjuvant therapy for early-stage breast cancer in postmenopausal women, focusing on the largest adjuvant breast cancer study till date to provide data, the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial.

Sign in / Sign up

Export Citation Format

Share Document